Home > Cardiology > AHA 2019 > Interventional Management for Acute Coronary Syndrome > Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy

Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy

Presented By
Prof. Usman Baber, Icahn School of Medicine at Mount Sinai, USA
Conference
AHA 2019
Trial
TWILIGHT

In a sub-analysis of the TWILIGHT trial, which looked only at patients with acute coronary syndrome (ACS), researchers confirmed that dropping aspirin after 3 months of dual antiplatelet therapy (DAPT) with ticagrelor following percutaneous coronary intervention (PCI) lowers bleeding risk without increasing the rate of ischaemic events. The benefit observed with ticagrelor monotherapy was independent of risk levels or whether the patients had non-ST elevation myocardial infarction (NSTEMI) or unstable angina at presentation.

Prof. Usman Baber (Icahn School of Medicine at Mount Sinai, USA) provided the rationale behind this particular sub-analysis: “The basis for DAPT in ACS really comes from trials conducted almost 20 years ago showing that it is superior to aspirin,” but he noted that “one of the challenges we have with the provision of antiplatelet therapy right now is that a lot of patients w...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on